Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination With IPI-549 Compared to Nivolumab Monotherapy in the Treatment of Patients With Immune Therapy-Naive, Advanced Urothelial Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Eganelisib (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms MARIO-275
- Sponsors Infinity Pharmaceuticals
- 13 Apr 2023 According to an Infinity Pharmaceutical media release, translational data showing increased systemic immune activation in patients treated with nivolumab in combination with eganelisib over nivolumab alone, with enrichment of genes from interferon signaling, antigen presentation, and T cell receptor pathways will be presented at the 2023 Annual Meeting of the American Association of Cancer Research (AACR) to be held April 14 - 19, 2023 in Orlando, Florida.
- 22 Nov 2022 Status changed from active, no longer recruiting to completed.
- 29 Jul 2022 According to an Infinity Pharmaceutical media release, the company has revealed positive two-year survival analysis of the trial.